Decreased contractility and altered responses to inotropic agents in myocytes from tachypacing-induced heart failure canines

J Pharmacol Toxicol Methods. 2018 Sep-Oct:93:98-107. doi: 10.1016/j.vascn.2018.06.001. Epub 2018 Jun 14.

Abstract

Contractility measurements using primary isolated cardiac myocytes (CM) have commonly been used in understanding the physiology and pharmacology of cellular mechanics. In the majority of studies, CM from healthy animals were used, and fewer studies were performed with CM from diseased hearts. To better understand the translational value of contractility on the cellular level of a diseased animal model, myocytes were isolated from left ventricles of a tachypacing-induced heart failure (HF) canine model, and their contractility was measured by recording sarcomere shortening using an image-based IonOptix video system. A side-by-side comparison study was performed in myocytes isolated from 13 normal and 5 tachypacing-induced HF canines by evaluating both basal contractility and pharmacological responses to inotropic agents with different mechanisms, including dobutamine, isoproterenol, milrinone, levosimendan, pimobendan, diltiazem, and flecainide. Myocytes isolated from HF canines exhibited compromised contractility at the sarcomere level in comparison to normal myocytes, specifically, HF myocytes have smaller sarcomere contraction amplitude, longer resting sarcomere length, slower velocity of contraction and relaxation. In addition, they have altered pharmacological responses compared to that of normal canines, with much less potent effects observed in the application of classic inotropic agents, such as isoproterenol, dobutamine, and milrinone. These results indicate that myocytes isolated from tachy-paced HF canines have altered physiological and pharmacological properties, which could be utilized for understanding pathophysiology and developing pharmacological interventions for HF.

Keywords: Animal model; Canines; Contractility; Heart failure; Isolated myocytes; Negative inotropes; Positive inotropes; Sarcomere shortening; Tachycardia.

MeSH terms

  • Animals
  • Cardiac Pacing, Artificial / adverse effects*
  • Cardiotonic Agents / pharmacology*
  • Cells, Cultured
  • Dogs
  • Dose-Response Relationship, Drug
  • Heart Failure / etiology*
  • Heart Failure / pathology
  • Heart Failure / physiopathology
  • Isoproterenol / pharmacology
  • Male
  • Myocardial Contraction / drug effects*
  • Myocardial Contraction / physiology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / physiology

Substances

  • Cardiotonic Agents
  • Isoproterenol